Αθηροσκλήρωσησ

32 Θ.Δ. Γκόσιος και συν16. Celebi AS, Yalcin H, Yalcin F. Current cardiac imaging techniquesfor detection of left ventricular mass. Cardiovasc Ultrasound 2010,8:1917. Ciulla M, Paliotti R, Hess DB et al. Echocardiographic patternsof myocardial fibrosis in hypertensive patients: endomyocardialbiopsy versus ultrasonic tissue characterization. J Am SocEchocardiogr 1997, 10:657–66418. Picano E, Pelosi G, Marzilli M et al. In vivo quantitative ultrasonicevaluation of myocardial fibrosis in humans. Circulation 1990,81:58–6419. Bombardini T, Galli R, Paterni M et al. A videodensitometric studyof transmural heterogeneity of cyclic echo amplitude variation inhuman myocardium. Am J Cardiol 1996, 78:212–21620. Rudolph A, Abdel-Aty H, Bohl S et al. Noninvasive detection offibrosis applying contrast-enhanced cardiac magnetic resonancein different forms of left ventricular hypertrophy relation toremodeling. J Am Coll Cardiol 2009, 53:284–29121. Andersen K, Hennersdorf M, Cohnen M et al. Myocardial delayedcontrast enhancement in patients with arterial hypertension:initial results of cardiac MRI. Eur J Radiol 2009, 71:75–8122. Moreo A, Ambrosio G, De Chiara B et al. Influence of myocardialfibrosis on left ventricular diastolic function: non-invasiveassessment by cardiac magnetic resonance and echo. CircCardiovasc Imag 2009, 2:437–44323. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence andfrequency of arrhythmias in hypertrophic cardiomyopathy inrelation to delayed enhancement on cardiovascular magneticresonance. J Am Coll Cardiol 2008, 51:1369–137424. Leonardi S, Raineri C, De Ferrari GM et al. Usefulness of cardiacmagnetic resonance in assessing the risk of ventricular arrhythmiasand sudden death in patients with hypertrophic cardiomyopathy.Eur Heart J 2009, 30:2003–201025. O’Hanlon R, Grasso A, Roughton M et al. Prognostic significanceof myocardial fibrosis in hypertrophic cardiomyopathy. J Am CollCardiol 2010, 56:867–87426. Maceira AM, Barba J, Varo N et al. Ultrasonic backscatter andserum marker of cardiac fibrosis in hypertensives. Hypertension2002, 39:923–92827. Ho CY, López B, Coelho-Filho OR et al. Myocardial fibrosis asan early manifestation of hypertrophic cardiomyopathy. N Engl JMed 2010, 363:552–56328. Li-Saw-Hee FL, Edmunds E, Blann AD et al. Matrix metalloproteinase-9and tissue inhibitor metalloproteinase-1 levels inessential hypertension. Relationship to left ventricular mass andanti-hypertensive therapy. Int J Cardiol 2000, 75:43–4729. Martos R, Baugh J, Ledwidge M et al. Diagnosis of heart failurewith preserved ejection fraction: improved accuracy with the useof markers of collagen turnover. Eur J Heart Fail 2009, 11:191–19730. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure:evidence of increased myocardial collagen turnover linked todiastolic dysfunction. Circulation 2007, 115:888–89531. González A, López B, Querejeta R et al. Filling pressures andcollagen metabolism in hypertensive patients with heart failureand normal ejection fraction. Hypertension 2010, 55:1418–142432. López B, González A, Querejeta R et al. Alterations in the patternof collagen deposition may contribute to the deterioration ofsystolic function in hypertensive patients with heart failure. J AmColl Cardiol 2006, 48:89–9633. Muiesan ML, Salvetti M, Rizzoni D et al. Persistence of leftventricular hypertrophy is a stronger indicator of cardiovascularevents than baseline left ventricular mass or systolic performance:10 years of follow-up. J Hypertens Suppl 1996, 14:43–4934. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression ofechocardiographic left ventricular hypertrophy after 2 years oftherapy reduces cardiovascular risk in patients with essentialhypertension. Am J Hypertens 2008, 21:464–47035. Verdecchia P, Angeli F, Gattobigio R et al. Regression of leftventricular hypertrophy and prevention of stroke in hypertensivesubjects. Am J Hypertens 2006, 19:493–49936. Okin PM, Gerdts E, Wachtell K et al. Relationship of leftatrial enlargement to persistence or development of ECG leftventricular hypertrophy in hypertensive patients: implicationsfor the development of new atrial fibrillation. J Hypertens 2010,28:1534–154037. Okin PM, Wachtell K, Devereux RB et al. Regression ofelectrocardiographic left ventricular hypertrophy and decreasedincidence of new-onset atrial fibrillation in patients withhypertension. JAMA 2006, 296:1242–124838. Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographicleft ventricular hypertrophy during antihypertensivetreatment and the prediction of major cardiovascular events.JAMA 2004, 292:2343–234939. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significanceof left ventricular mass change during treatment of hypertension.JAMA 2004, 292:2350–235640. Okin PM, Devereux RB, Harris KE et al. Regression of electrocardiographicleft ventricular hypertrophy is associated with lesshospitalization for heart failure in hypertensive patients. AnnIntern Med 2007, 147:311–31941. Mathew J, Sleight P, Lonn E et al. Reduction of cardiovascular riskby regression of electrocardiographic markers of left ventricularhypertrophy by the angiotensin-converting enzyme inhibitorramipril. Circulation 2001, 104:1615–162142. Svensson P, de Faire U, Sleight P et al. Comparative effects oframipril on ambulatory and office blood pressures: a HOPESubstudy. Hypertension 2001, 38:28–3243. Pierdomenico SD, Cuccurullo F. Risk reduction after regression ofechocardiographic left ventricular hypertrophy in hypertension:a meta-analysis. Am J Hypertens 2010, 23:876–88144. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascularrisk by reduction of left ventricular mass in hypertension: a metaanalysis.Am J Hypertens 2003, 16:895–89945. Devereux RB, Palmieri V, Sharpe N et al. Effects of once-dailyangiotensin-converting enzyme inhibition and calcium channelblockade-based antihypertensive treatment regimens on leftventricular hypertrophy and diastolic filling in hypertension: theprospective randomized enalapril study evaluating regressionof ventricular enlargement (preserve) trial. Circulation 2001,104:1248–125446. Terpstra WF, May JF, Smit AJ et al. Long-term effects of amlodipineand lisinopril on left ventricular mass and diastolic function inelderly, previously untreated hypertensive patients: the ELVERAtrial. J Hypertens 2001, 19:303–30947. Ruggenenti P, Iliev I, Costa GM et al. Preventing left ventricularhypertrophy by ACE inhibition in hypertensive patients with type2 diabetes: a prespecified analysis of the Bergamo NephrologicDiabetes Complications Trial (BENEDICT). Diabet Care 2008,31:1629–163448. Dahlöf B, Hansson L. Regression of left ventricular hypertrophyin previously untreated essential hypertension: different effectsof enalapril and hydrochlorothiazide. J Hypertens 1992, 10:1513–1524© 2011 Ελληνική Εταιρεία Αθηροσκλήρωσης